Capitalising on the results of EU-OS-DRIVE (grant agreement No 823893), DRIVE II aims at progressing the EU-OS ERIC as a sustainable world-class RI running excellent operations and services in a sustainable manner. EU-OS plays an important role in facilitating the drug discovery process in Europe, and DRIVE II will provide the tools to strengthen this process by i) enlarging the membership of the current ERIC countries (CZ (2018), DK (2019), FI (2018), DE (2018), LV (2018), NO (2018), PL (2018), PT (2022), ES (2018), SE (2022) and improving international cooperation; ii) improving the management processes needed for a large, distributed infrastructure, iii) growing capacity and competence to address current needs in the early drug discovery and support EU life science industry by expanding i) its compound collections with other compound libraries such as for example DNA-encoded libraries, ii) its services by integrating chemical proteomics capabilities to support the identification of drug-target interactions and CRISPR/siRNA methods, virtual screening to complement the HTS hit identification with other hit/lead generation methods and iii) by hit validation modalities using more physiologically relevant cellular models such as patient-derived cells and 3D models for a swift translation of preclinical results into clinical use. EU-OS-DRIVE II will ensure open and unrestricted access to their research data delivering its added-value via constant re-use of generated data (e.g. AI/ machine learning) and tools by users across the globe with the aim to reinforce global competitiveness not only of the RI, but also of the European Research Area.  

Publikace